Key facts
- This page summarizes Eric Lefebvre's Form 4 filing for PLIANT THERAPEUTICS, INC. (PLRX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 25 Jan 2023, 20:00.
Eric Lefebvre - 23 Jan 2023 Form 4 Insider Report for PLIANT THERAPEUTICS, INC. (PLRX)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- PLRX
- Reported as of
- 23 Jan 2023
- Net transaction value
- -$2,327,630
- SEC form
- 4
- Accepted by SEC
- 25 Jan 2023, 20:00:38 UTC
- Prior SEC filing
- 21 Dec 2022
- Next SEC filing
- 27 Jan 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mike Ouimette, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Eric Lefebvre filed Form 4 for PLIANT THERAPEUTICS, INC. (PLRX) on 25 Jan 2023.
Change
- Previous filing in this sequence was filed on 21 Dec 2022.
- Current net transaction value: -$2,327,630.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PLRX
transaction
Common Stock
Sale
- Transaction value
- $2,327,630
- Shares
- -67,500
- Change %
- -47%
- Price
- $34.48
- Shares after
- 76,926
- Date
- 23 Jan 2023
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 13, 2022.